Regenerative Medicine
and Exosome Column

A special update on the May 2026 insurance coverage news, organized around how regenerative medicine is changing as it moves beyond self-pay treatment.

A special update on the April 21, 2026 Fukuoka case, focusing on the process-level link to the fatal case discussed in Episode 1 and what readers should examine carefully.

This article organizes why anxiety spread after two reported cases, how to separate cell therapy from exosome-based approaches, what to look for in a clinic's management system, and which questions matter before choosing where to consult.

This article explains the differences among stem cell therapy, exosomes, and conditioned medium, and offers a calm starting point for understanding why regenerative medicine should not be treated as one single category.

This article explains why exosomes are often described as safer than cell therapy, what that claim really means, and which checkpoints still matter before deciding where to consult.

This article explains how to tell whether a regenerative medicine clinic is trustworthy, which warning signs should prompt caution, and what to ask before deciding to book a consultation.

This article organizes the points to check before consultation, how to think about who may be a good fit, and which cases should be approached more cautiously.

This article explains how to organize your condition, questions, and documents before a consultation so the discussion can move forward calmly and clearly.

This article explains the usual sequence from inquiry and information gathering to physician assessment and deciding whether to proceed with treatment.

This article explains how to choose a good clinic by checking how clearly the treatment is explained, how the physician is involved, and how quality control is handled.

This episode answers common questions about regenerative medicine and exosomes in a gentle Q&A format, covering effectiveness, safety, side effects, costs, and consultation flow.